



## Proton Therapy Promises and Perils: What Progress Has Been Made?

Guest Editor:

**Dr. Charles Bloch**

Clinical Physics Lead, Proton Therapy, Department of Radiation Oncology, University of Washington School of Medicine  
Associate Director of Medical Physics, Seattle Proton Therapy Center, 1570 N. 115th Street, Seattle, WA 98113, USA

Deadline for manuscript submissions:

**closed (31 March 2024)**

### Message from the Guest Editor

In 2009, AAPM hosted a special symposium on “The Promises and Perils of Proton Radiotherapy”. At that time, there were less than 10 proton therapy facilities operating in the US. Currently, there are 39 proton therapy centers in the US, and we are on the verge of building a carbon ion therapy center. This issue will attempt to look at the progress achieved since then. Intensity-modulated proton therapy (IMPT) has become the standard method of delivery. Medical physicists tout the promise of proton therapy as exhibited by the superior depth-dose deposition. Practitioners enjoy treatment plans able to spare large volumes of normal tissue. Meanwhile, substantial improvements in clinical outcomes are less easy to conclusively demonstrate. Has proton therapy lived up to our expectations? What new clinical evidence do we have supporting protons? What perils do we still need to address? How are uncertainties being managed? Is cost still a major issue? Is this the future we saw, and if not, when do we expect it?

In this Special Issue, we invite articles addressing clinical topics, both successes and work remaining to be carried out.





# cancers



an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Samuel C. Mok**

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI